CoChat
Sign Up
Cited by 551

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

APOBECs and virus restriction

Harris, Reuben S., Dudley, Jaquelin P.·2015·Virology
DOI 10.1016/j.virol.2015.03.012PMC PMC4424171
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.virol.2015.03.012

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The seven APOBEC3 subfamilies (including A3A to A3H) restrict DNA and RNA viruses.

    “The seven APOBEC3 subfamilies (including A3A to A3H) are reported to restrict DNA and RNA viruses (reviewed in Refs.21,22).”

    From The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness (2022) · cites this paper as [21]

    The ‘Positive selection and copy number variation’ section (page unavailable) identifies seven human APOBEC3 genes. The HIV-restriction section reports restriction by A3D, A3F, A3G and A3H, while ‘DNA viruses and the APOBEC family’ describes restriction by other APOBEC3 members. The review therefore supports restriction of RNA retroviruses and DNA viruses by APOBEC3 proteins, but not the implication that all seven have been shown to restrict both types. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • APOBEC proteins play an important role in immune responses against DNA and RNA viral pathogens.

    “Since APOBEC proteins play an important role in immune responses against DNA and RNA viral pathogens (Refs.19–22 and references therein), we also investigated the possible effects of the three APOBECs on SARS-CoV-2 replication and progeny production in our experimental system (Fig. 5A).”

    From The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness (2022) · cites this paper as [21]

  • The APOBEC proteins are a family of cytosine deaminases that can deaminate cytosine to uracil (C-to-U) in single-stranded nucleic acids and function in innate and adaptive immune responses to viral pathogens.

    “The APOBEC proteins are a family of cytosine deaminases that can deaminate cytosine to uracil (C-to-U) in single-stranded nucleic acids and function in a variety of biological processes, including innate and adaptive immune responses to viral pathogens (Refs.19–22 and references therein).”

    From The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness (2022) · cites this paper as [21]

  • The pro-viral effect of A3A contrasts with the known anti-viral effect of APOBECs.

    “These pro-viral effect of A3A contrast to the known anti-viral effect of APOBECs19–22.”

    From The roles of APOBEC-mediated RNA editing in SARS-CoV-2 mutations, replication and fitness (2022) · cites this paper as [21]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 236

  1. Abudu, 2006, Murine retrovirus escapes from murine APOBEC3 via two distinct novel mechanisms, Curr. Biol., 16, 1565, 10.1016/j.cub.2006.06.055 · DOI
  2. Ai, 2014, Core-binding factor subunit beta is not required for non-primate lentiviral Vif-mediated APOBEC3 degradation, J. Virol., 88, 12112, 10.1128/JVI.01924-14 · DOI
  3. Albin, 2014, Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus, Virology, 450–451, 49, 10.1016/j.virol.2013.11.041 · DOI
  4. Alce, 2004, APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein, J. Biol. Chem., 279, 34083, 10.1074/jbc.C400235200 · DOI
  5. Alke, 2001, The bet gene of feline foamy virus is required for virus replication, Virology, 287, 310, 10.1006/viro.2001.1065 · DOI
  6. Anwar, 2013, Footprint of APOBEC3 on the genome of human retroelements, J. Virol., 87, 8195, 10.1128/JVI.00298-13 · DOI
  7. Apolonia, 2015, Promiscuous RNA binding ensures effective encapsidation of APOBEC3 proteins by HIV-1, PLoS Pathog., 11, e1004609, 10.1371/journal.ppat.1004609 · DOI
  8. Aydin, 2014, Structure-guided analysis of the human APOBEC3-HIV restrictome, Structure, 22, 668, 10.1016/j.str.2014.02.011 · DOI
  9. Bangham, 2014, HTLV-1 clonality in adult T-cell leukaemia and non-malignant HTLV-1 infection, Semin. Cancer Biol., 26, 89, 10.1016/j.semcancer.2013.11.003 · DOI
  10. Bannert, 2004, Retroelements and the human genome: new perspectives on an old relation, Proc. Natl. Acad. Sci. USA, 101, S14572, 10.1073/pnas.0404838101 · DOI
  11. Barrett, 2014, Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo, Virology, 468–470, 601, 10.1016/j.virol.2014.09.006 · DOI
  12. Baunach, 1993, Functional analysis of human foamy virus accessory reading frames, J. Virol., 67, 5411, 10.1128/jvi.67.9.5411-5418.1993 · DOI · Paper page
  13. Beggel, 2013, Full genome ultra-deep pyrosequencing associates G-to-A hypermutation of the hepatitis B virus genome with the natural progression of hepatitis B, J. Viral Hepat., 20, 882, 10.1111/jvh.12110 · DOI
  14. Bekerman, 2013, A role for host activation-induced cytidine deaminase in innate immune defense against KSHV, PLoS Pathog., 9, e1003748, 10.1371/journal.ppat.1003748 · DOI
  15. Berkhout, 2004, APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations, AIDS, 18, 1861, 10.1097/00002030-200409030-00022 · DOI
  16. Berlioz, 1995, An internal ribosomal entry mechanism promotes translation of murine leukemia virus gag polyprotein precursors, J. Virol., 69, 2214, 10.1128/jvi.69.4.2214-2222.1995 · DOI
  17. Bhadra, 2009, BALB/Mtv-null mice responding to strong mouse mammary tumor virus superantigens restrict mammary tumorigenesis, J. Virol., 83, 484, 10.1128/JVI.01374-08 · DOI
  18. Bishop, 2004, Cytidine deamination of retroviral DNA by diverse APOBEC proteins, Curr. Biol., 14, 1392, 10.1016/j.cub.2004.06.057 · DOI
  19. Bogerd, 2008, Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation, RNA, 14, 1228, 10.1261/rna.964708 · DOI
  20. Bogerd, 2006, APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells, Nucleic Acids Res., 34, 89, 10.1093/nar/gkj416 · DOI
  21. Bogerd, 2006, Cellular inhibitors of long interspersed element 1 and Alu retrotransposition, Proc. Natl. Acad. Sci. USA, 103, 8780, 10.1073/pnas.0603313103 · DOI
  22. Bohn, 2013, Crystal structure of the DNA cytosine deaminase APOBEC3F: the catalytically active and HIV-1 Vif-binding domain, Structure, 21, 1042, 10.1016/j.str.2013.04.010 · DOI
  23. Boi, 2014, Incorporation of mouse APOBEC3 into murine leukemia virus virions decreases the activity and fidelity of reverse transcriptase, J. Virol., 88, 7659, 10.1128/JVI.00967-14 · DOI
  24. Bonvin, 2006, Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication, Hepatology, 43, 1364, 10.1002/hep.21187 · DOI
  25. Bonvin, 2008, Hepatitis B: modern concepts in pathogenesis—APOBEC3 cytidine deaminases as effectors in innate immunity against the hepatitis B virus, Curr. Opin. Infect. Dis., 21, 298, 10.1097/QCO.0b013e3282fe1bb2 · DOI
  26. Brightman, 1990, Preleukemic hematopoietic hyperplasia induced by Moloney murine leukemia virus is an indirect consequence of viral infection, J. Virol., 64, 4582, 10.1128/jvi.64.9.4582-4584.1990 · DOI
  27. Browne, 2009, Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent, Virology, 387, 313, 10.1016/j.virol.2009.02.026 · DOI
  28. Burns, 2013, Evidence for APOBEC3B mutagenesis in multiple human cancers, Nat. Genet., 45, 977, 10.1038/ng.2701 · DOI
  29. Byeon, 2013, NMR structure of human restriction factor APOBEC3A reveals substrate binding and enzyme specificity, Nat. Commun., 4, 1890, 10.1038/ncomms2883 · DOI
  30. Byun, 2012, Requirements for mouse mammary tumor virus Rem signal peptide processing and function, J. Virol., 86, 214, 10.1128/JVI.06197-11 · DOI
  31. Byun, 2010, Retroviral Rem protein requires processing by signal peptidase and retrotranslocation for nuclear function, Proc. Natl. Acad. Sci. USA, 107, 12287, 10.1073/pnas.1004303107 · DOI
  32. Cai, 2005, Kaposi׳s sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells, Proc. Natl. Acad. Sci. USA, 102, 5570, 10.1073/pnas.0408192102 · DOI
  33. Carpenter, 2010, Determinants of sequence-specificity within human AID and APOBEC3G, DNA Repair, 9, 579, 10.1016/j.dnarep.2010.02.010 · DOI
  34. Chareza, 2012, Molecular and functional interactions of cat APOBEC3 and feline foamy and immunodeficiency virus proteins: different ways to counteract host-encoded restriction, Virology, 424, 138, 10.1016/j.virol.2011.12.017 · DOI
  35. Chaurasiya, 2014, Oligomerization transforms human APOBEC3G from an efficient enzyme to a slowly dissociating nucleic acid-binding protein, Nat. Chem., 6, 28, 10.1038/nchem.1795 · DOI
  36. Chen, 2006, APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons, Curr. Biol., 16, 480, 10.1016/j.cub.2006.01.031 · DOI
  37. Chen, 2008, Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G, Nature, 452, 116, 10.1038/nature06638 · DOI
  38. Chiu, 2006, High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition, Proc. Natl. Acad. Sci. USA, 103, 15588, 10.1073/pnas.0604524103 · DOI
  39. Conticello, 2008, The AID/APOBEC family of nucleic acid mutators, Genome Biol., 9, 229, 10.1186/gb-2008-9-6-229 · DOI
  40. Conticello, 2003, The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G, Curr. Biol., 13, 2009, 10.1016/j.cub.2003.10.034 · DOI
  41. Conticello, 2005, Evolution of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases, Mol. Biol. Evol., 22, 367, 10.1093/molbev/msi026 · DOI
  42. Davis, 1987, Characterization of a preleukemic state induced by Moloney murine leukemia virus: evidence for two infection events during leukemogenesis, Proc. Natl. Acad. Sci. USA, 84, 4875, 10.1073/pnas.84.14.4875 · DOI
  43. Derse, 2007, Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid, Proc. Natl. Acad. Sci. USA, 104, 2915, 10.1073/pnas.0609444104 · DOI
  44. Desimmie, 2014, Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all, J. Mol. Biol., 426, 1220, 10.1016/j.jmb.2013.10.033 · DOI
  45. Di Noia, 2007, Molecular mechanisms of antibody somatic hypermutation, Annu. Rev. Biochem., 76, 1, 10.1146/annurev.biochem.76.061705.090740 · DOI
  46. Dittmer, 1998, A cluster of latently expressed genes in Kaposi׳s sarcoma-associated herpesvirus, J. Virol., 72, 8309, 10.1128/JVI.72.10.8309-8315.1998 · DOI
  47. Doehle, 2006, The betaretrovirus Mason–Pfizer monkey virus selectively excludes simian APOBEC3G from virion particles, J. Virol., 80, 12102, 10.1128/JVI.01600-06 · DOI
  48. Doehle, 2005, Differential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion, J. Virol., 79, 8201, 10.1128/JVI.79.13.8201-8207.2005 · DOI
  49. Donahue, 2015, Genetic analysis of the localization of APOBEC3F to human immunodeficiency virus type 1 virion cores, J. Virol., 89, 2415, 10.1128/JVI.01981-14 · DOI
  50. Douaisi, 2004, HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles, Biochem. Biophys. Res. Commun., 321, 566, 10.1016/j.bbrc.2004.07.005 · DOI
  51. Duggal, 2013, Identification and antiviral activity of common polymorphisms in the APOBEC3 locus in human populations, Virology, 443, 329, 10.1016/j.virol.2013.05.016 · DOI
  52. Dutko, 2005, Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases, Curr. Biol., 15, 661, 10.1016/j.cub.2005.02.051 · DOI
  53. Ebrahimi, 2012, APOBEC3G and APOBEC3F rarely co-mutate the same HIV genome, Retrovirology, 9, 113, 10.1186/1742-4690-9-113 · DOI
  54. Endo, 2007, Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling, Oncogene, 26, 5587, 10.1038/sj.onc.1210344 · DOI
  55. Esnault, 2005, APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses, Nature, 433, 430, 10.1038/nature03238 · DOI
  56. Esnault, 2006, Dual inhibitory effects of APOBEC family proteins on retrotransposition of mammalian endogenous retroviruses, Nucleic Acids Res., 34, 1522, 10.1093/nar/gkl054 · DOI
  57. Fan, 2010, APOBEC3G generates nonsense mutations in human T-cell leukemia virus type 1 proviral genomes in vivo, J. Virol., 84, 7278, 10.1128/JVI.02239-09 · DOI · Paper page
  58. Feng, 2014, Suppression of APOBEC3-mediated restriction of HIV-1 by Vif, Front. Microbiol., 5, 450, 10.3389/fmicb.2014.00450 · DOI
  59. Fujisawa, 1997, Characterization of glycosylated Gag expressed by a neurovirulent murine leukemia virus: identification of differences in processing in vitro and in vivo, J. Virol., 71, 5355, 10.1128/jvi.71.7.5355-5360.1997 · DOI
  60. Gabuzda, 1992, Role of Vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes, J. Virol., 66, 6489, 10.1128/jvi.66.11.6489-6495.1992 · DOI
  61. Gillick, 2013, Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination, J. Virol., 87, 1508, 10.1128/JVI.02587-12 · DOI
  62. Golovkina, 1992, Transgenic mouse mammary tumor virus superantigen expression prevents viral infection, Cell, 69, 637, 10.1016/0092-8674(92)90227-4 · DOI
  63. Golovkina, 1998, B and T cells are required for mouse mammary tumor virus spread within the mammary gland, J. Immunol., 161, 2375, 10.4049/jimmunol.161.5.2375 · DOI
  64. Gourzi, 2006, A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus, Immunity, 24, 779, 10.1016/j.immuni.2006.03.021 · DOI
  65. Gourzi, 2007, Viral induction of AID is independent of the interferon and the toll-like receptor signaling pathways but requires NF-kappaB, J. Exp. Med., 204, 259, 10.1084/jem.20061801 · DOI
  66. Haché, 2005, The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain, J. Biol. Chem., 280, 10920, 10.1074/jbc.M500382200 · DOI
  67. Haché, 2006, Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance, AIDS Rev., 8, 148
  68. Hakata, 2006, Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains, J. Biol. Chem., 281, 36624, 10.1074/jbc.M604980200 · DOI
  69. Halemano, 2014, Immunoglobulin somatic hypermutation by APOBEC3/Rfv3 during retroviral infection, Proc. Natl. Acad. Sci. USA, 111, 7759, 10.1073/pnas.1403361111 · DOI
  70. Han, 2014, Evolutionarily conserved requirement for core binding factor beta in the assembly of the human immunodeficiency virus/simian immunodeficiency virus Vif-cullin 5-RING E3 ubiquitin ligase, J. Virol., 88, 3320, 10.1128/JVI.03833-13 · DOI
  71. Harjes, 2013, Impact of H216 on the DNA binding and catalytic activities of the HIV restriction factor APOBEC3G, J. Virol., 87, 7008, 10.1128/JVI.03173-12 · DOI
  72. Harris, 2003, DNA deamination mediates innate immunity to retroviral infection, Cell, 113, 803, 10.1016/S0092-8674(03)00423-9 · DOI
  73. Harris, 2012, The restriction factors of human immunodeficiency virus, J. Biol. Chem., 287, 40875, 10.1074/jbc.R112.416925 · DOI
  74. Harris, 2004, Retroviral restriction by APOBEC proteins, Nat. Rev. Immunol., 4, 868, 10.1038/nri1489 · DOI
  75. Harris, 2002, RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators, Mol. Cell, 10, 1247, 10.1016/S1097-2765(02)00742-6 · DOI
  76. Held, 1993, Superantigen-reactive CD4+ T cells are required to stimulate B cells after infection with mouse mammary tumor virus, J. Exp. Med., 177, 359, 10.1084/jem.177.2.359 · DOI
  77. Held, 1993, Superantigen-induced immune stimulation amplifies mouse mammary tumor virus infection and allows virus transmission, Cell, 74, 529, 10.1016/0092-8674(93)80054-I · DOI
  78. Henderson, 2014, APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development, Cell Rep., 7, 1833, 10.1016/j.celrep.2014.05.012 · DOI
  79. Henry, 2012, Evolution of the primate APOBEC3A cytidine deaminase gene and identification of related coding regions, PLoS One, 7, e30036, 10.1371/journal.pone.0030036 · DOI
  80. Holmes, 2007, APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G, J. Biol. Chem., 282, 2587, 10.1074/jbc.M607298200 · DOI
  81. Holmes, 2007, APOBEC-mediated viral restriction: not simply editing?, Trends Biochem. Sci., 32, 118, 10.1016/j.tibs.2007.01.004 · DOI
  82. Holtz, 2013, APOBEC3G cytosine deamination hotspots are defined by both sequence context and single-stranded DNA secondary structure, Nucleic Acids Res., 41, 6139, 10.1093/nar/gkt246 · DOI
  83. Hultquist, 2011, Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1, J. Virol., 85, 11220, 10.1128/JVI.05238-11 · DOI
  84. Imahashi, 2014, Lack of association between intact/deletion polymorphisms of the APOBEC3B gene and HIV-1 risk, PLoS One, 9, e92861, 10.1371/journal.pone.0092861 · DOI
  85. Imahashi, 2012, Antiviral mechanism and biochemical basis of the human APOBEC3 family, Front. Microbiol., 3, 250, 10.3389/fmicb.2012.00250 · DOI
  86. Indik, 2005, A novel, mouse mammary tumor virus encoded protein with Rev-like properties, Virology, 337, 1, 10.1016/j.virol.2005.03.040 · DOI · Paper page
  87. Irshad, 2006, Transfusion transmitted virus: a review on its molecular characteristics and role in medicine, World J. Gastroenterol., 12, 5122, 10.3748/wjg.v12.i32.5122 · DOI
  88. Iwatani, 2007, Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G, Nucleic Acids Res., 35, 7096, 10.1093/nar/gkm750 · DOI
  89. Jaguva Vasudevan, 2013, Prototype foamy virus Bet impairs the dimerization and cytosolic solubility of human APOBEC3G, J. Virol., 87, 9030, 10.1128/JVI.03385-12 · DOI
  90. Janini, 2001, Human immunodeficiency virus type 1 DNA sequences genetically damaged by hypermutation are often abundant in patient peripheral blood mononuclear cells and may be generated during near-simultaneous infection and activation of CD4(+) T cells, J. Virol., 75, 7973, 10.1128/JVI.75.17.7973-7986.2001 · DOI
  91. Jarmuz, 2002, An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22, Genomics, 79, 285, 10.1006/geno.2002.6718 · DOI
  92. Jern, 2008, Effects of retroviruses on host genome function, Annu. Rev. Genet., 42, 709, 10.1146/annurev.genet.42.110807.091501 · DOI · Paper page
  93. Jern, 2009, Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance, PLoS Pathog., 5, e1000367, 10.1371/journal.ppat.1000367 · DOI
  94. Jern, 2007, Role of APOBEC3 in genetic diversity among endogenous murine leukemia viruses, PLoS Genet., 3, 2014, 10.1371/journal.pgen.0030183 · DOI
  95. Johnson, 2009, Molecular evolution of the antiretroviral TRIM5 gene, Immunogenetics, 61, 163, 10.1007/s00251-009-0358-y · DOI
  96. Jones, 2013, Protein-primed terminal transferase activity of hepatitis B virus polymerase, J. Virol., 87, 2563, 10.1128/JVI.02786-12 · DOI
  97. Jónsson, 2006, Evolutionarily conserved and non-conserved retrovirus restriction activities of artiodactyl APOBEC3F proteins, Nucleic Acids Res., 34, 5683, 10.1093/nar/gkl721 · DOI
  98. Kao, 2003, The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity, J. Virol., 77, 11398, 10.1128/JVI.77.21.11398-11407.2003 · DOI
  99. Kidd, 2007, Population stratification of a common APOBEC gene deletion polymorphism, PLoS Genet., 3, e63, 10.1371/journal.pgen.0030063 · DOI
  100. Kim, 2010, Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure, J. Virol., 84, 10402, 10.1128/JVI.01223-10 · DOI
  101. Kim, 2014, Human APOBEC3 induced mutation of human immunodeficiency virus type-1 contributes to adaptation and evolution in natural infection, PLoS Pathog., 10, e1004281, 10.1371/journal.ppat.1004281 · DOI
  102. Kinomoto, 2007, All APOBEC3 family proteins differentially inhibit LINE-1 retrotransposition, Nucleic Acids Res., 35, 2955, 10.1093/nar/gkm181 · DOI
  103. Kitamura, 2012, The APOBEC3C crystal structure and the interface for HIV-1 Vif binding, Nat. Struct. Mol. Biol., 19, 1005, 10.1038/nsmb.2378 · DOI
  104. Kobayashi, 2014, Quantification of deaminase activity-dependent and-independent restriction of HIV-1 replication mediated by APOBEC3F and APOBEC3G through experimental-mathematical investigation, J. Virol., 88, 5881, 10.1128/JVI.00062-14 · DOI
  105. Kohli, 2010, Local sequence targeting in the AID/APOBEC family differentially impacts retroviral restriction and antibody diversification, J. Biol. Chem., 285, 40956, 10.1074/jbc.M110.177402 · DOI
  106. Kolokithas, 2010, The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3, J. Virol., 84, 10933, 10.1128/JVI.01023-10 · DOI
  107. Kremer, 2006, Vaccinia virus replication is not affected by APOBEC3 family members, Virol. J., 3, 86, 10.1186/1743-422X-3-86 · DOI
  108. Krisko, 2013, HIV restriction by APOBEC3 in humanized mice, PLoS Pathog., 9, e1003242, 10.1371/journal.ppat.1003242 · DOI
  109. Langlois, 2009, The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3, J. Virol., 83, 11550, 10.1128/JVI.01430-09 · DOI
  110. LaRue, 2009, Guidelines for naming nonprimate APOBEC3 genes and proteins, J. Virol., 83, 494, 10.1128/JVI.01976-08 · DOI
  111. LaRue, 2008, The artiodactyl APOBEC3 innate immune repertoire shows evidence for a multi-functional domain organization that existed in the ancestor of placental mammals, BMC Mol. Biol., 9, 104, 10.1186/1471-2199-9-104 · DOI
  112. LaRue, 2010, Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity, J. Virol., 84, 8193, 10.1128/JVI.00685-10 · DOI
  113. Lassen, 2010, Identification of two APOBEC3F splice variants displaying HIV-1 antiviral activity and contrasting sensitivity to Vif, J. Biol. Chem., 285, 29326, 10.1074/jbc.M110.154054 · DOI
  114. Lee, 2008, Hypermutation of an ancient human retrovirus by APOBEC3G, J. Virol., 82, 8762, 10.1128/JVI.00751-08 · DOI
  115. Li, 2014, APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells, J. Mol. Biol., 426, 1296, 10.1016/j.jmb.2013.12.014 · DOI
  116. Li, 2012, Two genetic determinants acquired late in mus evolution regulate the inclusion of exon 5, which alters mouse APOBEC3 translation efficiency, PLoS Pathog., 8, e1002478, 10.1371/journal.ppat.1002478 · DOI
  117. Li, 2012, First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G, ACS Chem. Biol., 7, 506, 10.1021/cb200440y · DOI
  118. Li, 1990, Combined infection by Moloney murine leukemia virus and a mink cell focus-forming virus recombinant induces cytopathic effects in fibroblasts or in long-term bone marrow cultures from preleukemic mice, J. Virol., 64, 3701, 10.1128/jvi.64.8.3701-3711.1990 · DOI
  119. Liang, 2013, RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase, Proc. Natl. Acad. Sci. USA, 110, 2246, 10.1073/pnas.1221921110 · DOI
  120. Liddament, 2004, APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo, Curr. Biol., 14, 1385, 10.1016/j.cub.2004.06.050 · DOI
  121. Lochelt, 2005, The antiretroviral activity of APOBEC3 is inhibited by the foamy virus accessory Bet protein, Proc. Natl. Acad. Sci. USA, 102, 7982, 10.1073/pnas.0501445102 · DOI
  122. Low, 2007, Mutation in the glycosylated gag protein of murine leukemia virus results in reduced in vivo infectivity and a novel defect in viral budding or release, J. Virol., 81, 3685, 10.1128/JVI.01538-06 · DOI
  123. Low, 2009, Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene, Virology, 385, 455, 10.1016/j.virol.2008.11.051 · DOI
  124. Lucifora, 2014, Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA, Science, 343, 1221, 10.1126/science.1243462 · DOI
  125. Lukic, 2013, Identification of the feline foamy virus Bet domain essential for APOBEC3 counteraction, Retrovirology, 10, 76, 10.1186/1742-4690-10-76 · DOI
  126. MacDuff, 2009, AID can restrict L1 retrotransposition suggesting a dual role in innate and adaptive immunity, Nucleic Acids Res., 37, 1854, 10.1093/nar/gkp030 · DOI
  127. MacMillan, 2013, APOBEC3 inhibition of mouse mammary tumor virus infection: the role of cytidine deamination versus inhibition of reverse transcription, J. Virol., 87, 4808, 10.1128/JVI.00112-13 · DOI
  128. Madani, 1998, An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral vif protein, J. Virol., 72, 10251, 10.1128/JVI.72.12.10251-10255.1998 · DOI
  129. Mahieux, 2005, Extensive editing of a small fraction of human T-cell leukemia virus type 1 genomes by four APOBEC3 cytidine deaminases, J. Gen. Virol., 86, 2489, 10.1099/vir.0.80973-0 · DOI
  130. Malim, 2012, HIV restriction factors and mechanisms of evasion, Cold Spring Harb. Perspect. Med., 2, a006940, 10.1101/cshperspect.a006940 · DOI
  131. Marchetto, 2013, Differential L1 regulation in pluripotent stem cells of humans and apes, Nature, 503, 525, 10.1038/nature12686 · DOI
  132. Marin, 2003, HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation, Nat. Med., 9, 1398, 10.1038/nm946 · DOI
  133. Mesri, 1996, Human herpesvirus-8/Kaposi׳s sarcoma-associated herpesvirus is a new transmissible virus that infects B cells, J. Exp. Med., 183, 2385, 10.1084/jem.183.5.2385 · DOI
  134. Metzner, 2012, LINE-1 retroelements complexed and inhibited by activation induced cytidine deaminase, PLoS One, 7, e49358, 10.1371/journal.pone.0049358 · DOI
  135. Meyers, 1989, Lymphomas with acquired mouse mammary tumor virus proviruses resemble distinct prethymic and intrathymic phenotypes defined in vivo, J. Immunol., 142, 3342, 10.4049/jimmunol.142.9.3342 · DOI
  136. Meyerson, 2011, Two-stepping through time: mammals and viruses, Trends Microbiol., 19, 286, 10.1016/j.tim.2011.03.006 · DOI · Paper page
  137. Mikl, 2005, Mice deficient in APOBEC2 and APOBEC3, Mol. Cell. Biol., 25, 7270, 10.1128/MCB.25.16.7270-7277.2005 · DOI
  138. Moebes, 1997, Human foamy virus reverse transcription that occurs late in the viral replication cycle, J. Virol., 71, 7305, 10.1128/jvi.71.10.7305-7311.1997 · DOI
  139. Moris, 2014, AID and APOBECs span the gap between innate and adaptive immunity, Front. Microbiol., 5, 534, 10.3389/fmicb.2014.00534 · DOI
  140. Muckenfuss, 2006, APOBEC3 proteins inhibit human LINE-1 retrotransposition, J. Biol. Chem., 281, 22161, 10.1074/jbc.M601716200 · DOI
  141. Mulder, 2008, Cytidine deamination induced HIV-1 drug resistance, Proc. Natl. Acad. Sci. USA, 105, 5501, 10.1073/pnas.0710190105 · DOI
  142. Münk, 2008, Functions, structure, and read-through alternative splicing of feline APOBEC3 genes, Genome Biol., 9, R48, 10.1186/gb-2008-9-3-r48 · DOI
  143. Muramatsu, 2000, Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme, Cell, 102, 553, 10.1016/S0092-8674(00)00078-7 · DOI
  144. Mustafa, 2003, The type B leukemogenic virus truncated superantigen is dispensable for T-cell lymphomagenesis, J. Virol., 77, 3866, 10.1128/JVI.77.6.3866-3870.2003 · DOI
  145. Nabel, 2013, Nucleic acid determinants for selective deamination of DNA over RNA by activation-induced deaminase, Proc. Natl. Acad. Sci. USA, 110, 14225, 10.1073/pnas.1306345110 · DOI
  146. Nair, 2014, Biochemical and biological studies of mouse APOBEC3, J. Virol., 88, 3850, 10.1128/JVI.03456-13 · DOI
  147. Narvaiza, 2009, Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase, PLoS Pathog., 5, e1000439, 10.1371/journal.ppat.1000439 · DOI
  148. Navarro, 2005, Complementary function of the two catalytic domains of APOBEC3G, Virology, 333, 374, 10.1016/j.virol.2005.01.011 · DOI
  149. Newman, 2005, Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity, Curr. Biol., 15, 166, 10.1016/j.cub.2004.12.068 · DOI
  150. Nitta, 2012, Moloney murine leukemia virus glyco-gag facilitates xenotropic murine leukemia virus-related virus replication through human APOBEC3-independent mechanisms, Retrovirology, 9, 58, 10.1186/1742-4690-9-58 · DOI
  151. Noguchi, 2007, Dual effect of APOBEC3G on Hepatitis B virus, J. Gen. Virol., 88, 432, 10.1099/vir.0.82319-0 · DOI
  152. OhAinle, 2008, Antiretroelement activity of APOBEC3H was lost twice in recent human evolution, Cell Host Microbe, 4, 249, 10.1016/j.chom.2008.07.005 · DOI
  153. Okeoma, 2010, APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions, Cell Host Microbe, 8, 534, 10.1016/j.chom.2010.11.003 · DOI
  154. Okeoma, 2007, APOBEC3 inhibits mouse mammary tumour virus replication in vivo, Nature, 445, 927, 10.1038/nature05540 · DOI
  155. Okeoma, 2009, Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection, J. Virol., 83, 3486, 10.1128/JVI.02347-08 · DOI
  156. Okeoma, 2009, Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection, J. Virol., 83, 3029, 10.1128/JVI.02536-08 · DOI
  157. Ooms, 2013, HIV-1 Vif adaptation to human APOBEC3H haplotypes, Cell Host Microbe, 14, 411, 10.1016/j.chom.2013.09.006 · DOI
  158. Ooms, 2012, APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1, J. Virol., 86, 6097, 10.1128/JVI.06570-11 · DOI
  159. Ortiz, 2006, Patterns of evolution of host proteins involved in retroviral pathogenesis, Retrovirology, 3, 11, 10.1186/1742-4690-3-11 · DOI
  160. Pathak, 1990, Broad spectrum of in vivo forward mutations, hypermutations, and mutational hotspots in a retroviral shuttle vector after a single replication cycle: substitutions, frameshifts, and hypermutations, Proc. Natl. Acad. Sci. USA, 87, 6019, 10.1073/pnas.87.16.6019 · DOI
  161. Perkovic, 2009, Species-specific inhibition of APOBEC3C by the prototype foamy virus protein bet, J. Biol. Chem., 284, 5819, 10.1074/jbc.M808853200 · DOI
  162. Petersen-Mahrt, 2002, AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification, Nature, 418, 99, 10.1038/nature00862 · DOI
  163. Petit, 2009, Murine APOBEC1 is a powerful mutator of retroviral and cellular RNA in vitro and in vivo, J. Mol. Biol., 385, 65, 10.1016/j.jmb.2008.10.043 · DOI
  164. Pfeffer, 2005, Identification of microRNAs of the herpesvirus family, Nat. Methods, 2, 269, 10.1038/nmeth746 · DOI
  165. Pillai, 2008, Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3), Retrovirology, 5, 26, 10.1186/1742-4690-5-26 · DOI
  166. Prochnow, 2007, The APOBEC-2 crystal structure and functional implications for the deaminase AID, Nature, 445, 447, 10.1038/nature05492 · DOI
  167. Rathore, 2013, The local dinucleotide preference of APOBEC3G can be altered from 5′-CC to 5′-TC by a single amino acid substitution, J. Mol. Biol., 425, 4442, 10.1016/j.jmb.2013.07.040 · DOI
  168. Rausch, 2009, Dissecting APOBEC3G substrate specificity by nucleoside analog interference, J. Biol. Chem., 284, 7047, 10.1074/jbc.M807258200 · DOI
  169. Refsland, 2013, The APOBEC3 family of retroelement restriction factors, Curr. Top. Microbiol. Immunol., 371, 1
  170. Refsland, 2012, Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n, PLoS Pathog., 8, e1002800, 10.1371/journal.ppat.1002800 · DOI
  171. Refsland, 2014, Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity, PLoS Genet., 10, e1004761, 10.1371/journal.pgen.1004761 · DOI
  172. Richardson, 2014, APOBEC3A deaminates transiently exposed single-strand DNA during LINE-1 retrotransposition, eLife, 3, e02008, 10.7554/eLife.02008 · DOI
  173. Roberts, 2013, An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers, Nat. Genet., 45, 970, 10.1038/ng.2702 · DOI
  174. Rosales Gerpe, 2015, N-Linked glycosylation protects gammaretroviruses against deamination by APOBEC3 proteins, J. Virol., 89, 2342, 10.1128/JVI.03330-14 · DOI
  175. Rosler, 2004, Comment on “Inhibition of hepatitis B virus replication by APOBEC3G”, Science, 305, 1403, 10.1126/science.1100464 · DOI
  176. Rulli, 2008, Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses, J. Virol., 82, 6566, 10.1128/JVI.01357-07 · DOI
  177. Russell, 2005, Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors, J. Virol., 79, 8724, 10.1128/JVI.79.14.8724-8731.2005 · DOI
  178. Sadler, 2010, APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis, J. Virol., 84, 7396, 10.1128/JVI.00056-10 · DOI
  179. Salter, 2014, Structural insights for HIV-1 therapeutic strategies targeting Vif, Trends Biochem. Sci., 39, 373, 10.1016/j.tibs.2014.07.001 · DOI
  180. Samols, 2005, Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi׳s sarcoma-associated herpesvirus, J. Virol., 79, 9301, 10.1128/JVI.79.14.9301-9305.2005 · DOI
  181. Santiago, 2008, Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection, Science, 321, 1343, 10.1126/science.1161121 · DOI
  182. Sanville, 2010, Adaptive evolution of Mus Apobec3 includes retroviral insertion and positive selection at two clusters of residues flanking the substrate groove, PLoS Pathog., 6, e1000974, 10.1371/journal.ppat.1000974 · DOI
  183. Sasada, 2005, APOBEC3G targets human T-cell leukemia virus type 1, Retrovirology, 2, 32, 10.1186/1742-4690-2-32 · DOI
  184. Sato, 2014, APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model, PLoS Pathog., 10, e1004453, 10.1371/journal.ppat.1004453 · DOI
  185. Schafer, 2004, Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor, Virology, 328, 163, 10.1016/j.virol.2004.08.006 · DOI
  186. Schmitt, 2011, Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution, Virology, 419, 24, 10.1016/j.virol.2011.07.017 · DOI
  187. Schumacher, 2008, The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction, J. Virol., 82, 2652, 10.1128/JVI.02391-07 · DOI
  188. Schumacher, 2005, APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast, Proc. Natl. Acad. Sci. USA, 102, 9854, 10.1073/pnas.0501694102 · DOI
  189. Seppen, 2004, Unedited inhibition of HBV replication by APOBEC3G, J. Hepatol., 41, 1068, 10.1016/j.jhep.2004.10.008 · DOI
  190. Shandilya, 2014, A computational analysis of the structural determinants of APOBEC3׳s catalytic activity and vulnerability to HIV-1 Vif, Virology, 471–473, 105, 10.1016/j.virol.2014.09.023 · DOI
  191. Sheehy, 2002, Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein, Nature, 418, 646, 10.1038/nature00939 · DOI
  192. Sheehy, 2003, The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif, Nat. Med., 9, 1404, 10.1038/nm945 · DOI
  193. Simon, 1998, Evidence for a newly discovered cellular anti-HIV-1 phenotype, Nat. Med., 4, 1397, 10.1038/3987 · DOI
  194. Siu, 2013, Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F, Nat. Commun., 4, 2593, 10.1038/ncomms3593 · DOI
  195. Smith, 2011, Noninfectious retrovirus particles drive the APOBEC3/Rfv3 dependent neutralizing antibody response, PLoS Pathog., 7, e1002284, 10.1371/journal.ppat.1002284 · DOI
  196. Song, 2012, Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction, J. Biol. Chem., 287, 16965, 10.1074/jbc.M111.310839 · DOI
  197. Stavrou, 2013, Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex, Proc. Natl. Acad. Sci. USA, 110, 9078, 10.1073/pnas.1217399110 · DOI
  198. Stenglein, 2010, APOBEC3 proteins mediate the clearance of foreign DNA from human cells, Nat. Struct. Mol. Biol., 17, 222, 10.1038/nsmb.1744 · DOI
  199. Stenglein, 2006, APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism, J. Biol. Chem., 281, 16837, 10.1074/jbc.M602367200 · DOI
  200. Stopak, 2003, HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability, Mol. Cell, 12, 591, 10.1016/S1097-2765(03)00353-8 · DOI

200 of 236 shown

Cited by

Sorted by citations

Metadata

Authors
Harris, R. S., & Dudley, J. P.
Venue
Virology
Publisher
Elsevier BV
Published
2015-05
Volume
479-480
Pages
131-145
ISSN
0042-6822
DOI
10.1016/j.virol.2015.03.012
PMC
PMC4424171
Cited by
551
References
6
Language
en
Licence
Funders
NIH (R21 AI105710, R01 CA167053, R01 AI064046, P01 GM091743)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review